Skip to content

ABUS

Arbutus Biopharma Corp

NASDAQ · Healthcare · Biotechnology · US

$5.01
−1.18%
Ask drillr

Next report

Analyst consensus

Next report date
Nov 16, 2026
EPS estimate
-$0.02
Revenue estimate
$1.0M

Latest reported

Last report date
Aug 12, 2026
EPS actual
-$0.03
EPS estimate
-$0.02
Revenue actual
$1.0M
Revenue estimate
$700.0K

Track record

Trailing twelve quarters

EPS beats (12Q)
7
EPS misses (12Q)
3
EPS in line (12Q)
2
Avg surprise (4Q)
+762.5%
Revenue beats (12Q)
4
Reported history
Report dateEPS estimateEPS actualSurpriseRevenue actual
Aug 12, 2026-$0.02-$0.03Miss -50.00%$1.0M
May 13, 2026-$0.03$0.87Beat 3000.00%
Mar 23, 2026-$0.04-$0.01Beat 71.47%$1.1M
Nov 13, 2025-$0.06-$0.04Beat 28.57%$529.0K
Aug 6, 2025-$0.02$0.01Beat 150.00%$10.7M
May 14, 2025-$0.09-$0.13Miss -44.44%$1.8M
Mar 27, 2025-$0.08-$0.07Beat 12.50%$1.6M
Aug 1, 2024-$0.10-$0.11Miss -10.00%$1.7M
May 2, 2024-$0.10-$0.10In line$1.5M
Feb 29, 2024-$0.12-$0.12In line$2.1M
Aug 3, 2023-$0.12-$0.10Beat 16.67%$4.7M
May 4, 2023-$0.14-$0.10Beat 28.57%$6.7M

Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 16, 2026